Last $86.10 USD
Change Today +0.76 / 0.89%
Volume 100.0
SHPGF On Other Exchanges
Symbol
Exchange
SHPGF is not on other exchanges.
As of 5:20 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

Shire plc, together with its subsidiaries, operates as a specialty biopharmaceutical company. The company is engaged in the research, development, licensing, manufacturing, marketing, distribution, and sale of specialist medicines to meet significant unmet patient needs. Strategy The company’s strategy is to grow its business and deliver value to its stakeholders by focusing on significant unmet patient needs in specialist areas and providing more innovative treatments to more patients. Treatments for Neuroscience Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurobehavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is frequent and severe than is typically observed in individuals at a comparable level of development. Standard treatments include educational approaches, psychological therapies that may include behavior modification, and/or medication. VYVANSE/VENVANSE/ ELVANSE/TYVENSE VYVANSE is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The U.S. Food and Drug Administration (FDA) approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD, for adults and for adolescents aged 13 to 17. In addition VYVANSE is approved by the FDA for maintenance treatment, having been approved both as a maintenance treatment in adults with ADHD in 2012, and as a maintenance treatment in pediatrics and adolescents aged 6 to 17 in 2013. VYVANSE is available in the United States in six dosage strengths: 20mg, 30mg, 40mg, 50mg, 60mg and 70mg. VYVANSE was approved by Health Canada for the treatment of ADHD in paediatric patients aged 6 to 12, for adolescents and adults, and was launched in Canada. VENVANSE was granted marketing authorization by ANVISA, the Brazilian health authority, for the treatment of ADHD in children aged 6-12. ELVANSE/TYVENSE received a positive outcome from the European Decentralised Procedure in 2012. ELVANSE is indicated as part of a comprehensive treatment program for ADHD in children 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Product labelling has been agreed by and Marketing Authorization approvals granted in eight countries (the United Kingdom, Germany, Sweden, Spain, Norway, Finland, Denmark, and Ireland). ADDERALL XR ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5mg, 10mg, 15mg, 20mg, 25mg and 30mg capsules. The FDA approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in 2009. The company receives royalties from Impax’s sales of authorized generic ADDERALL XR. Shire has extended its supply agreement with Teva until September 30, 2016. In December 2013, the company entered an agreement with Sandoz Inc. (Sandoz) whereby Shire would supply Sandoz with an authorized generic version of Adderall XR beginning July 1, 2016. From the December 1, 2013, effective date of the agreement through the end of the agreement’s five-year term, Sandoz has agreed to exclusively sell the authorized generic version of Adderall XR supplied by the company. In 2012, the FDA stated that it would require that all abbreviated new drug applications (ANDAs) for ADDERALL XR would have to establish bioequivalence using partial area under the curve measurements at multiple time points post-dosing and for both d- and l-amphetamine. The FDA response is consistent with recent decisions on other long-acting ADHD products. INTUNIV INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex. The FDA approved INTUNIV

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPGF:US $86.10 USD +0.76

SHPGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $238.76 USD +3.92
Allergan Inc/United States $170.20 USD +1.64
Celgene Corp $92.57 USD +3.11
CSL Ltd A$72.60 AUD 0.00
Valeant Pharmaceuticals International Inc C$134.03 CAD -0.16
View Industry Companies
 

Industry Analysis

SHPGF

Industry Average

Valuation SHPGF Industry Range
Price/Earnings 31.3x
Price/Sales 9.4x
Price/Book 8.3x
Price/Cash Flow 46.4x
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.